↓ Skip to main content

Dove Medical Press

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors

Overview of attention for article published in Biologics: Targets & Therapy, April 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
29 Mendeley
Title
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
Published in
Biologics: Targets & Therapy, April 2012
DOI 10.2147/btt.s20677
Pubmed ID
Authors

Ursa Brown-Glaberman, Alison T Stopeck

Abstract

Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major source of morbidity for cancer patients with bone metastases. The receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation and activity in normal bone physiology as well as cancer-induced bone resorption. The first commercially available drug that specifically targets and inhibits the RANKL pathway is denosumab, a fully human monoclonal antibody that binds and neutralizes RANKL, thereby inhibiting osteoclast function. In this review, we summarize the major studies leading to the US Food and Drug Administration-approval of denosumab for the prevention of SREs in patients with bone metastases from solid tumors. Further, we discuss the role of denosumab in the prevention and treatment of SREs and bone loss in cancer patients. As a monoclonal antibody, denosumab has several advantages over bisphosphonates, including improved efficacy, better tolerability, and the convenience of administration by subcutaneous injection. In addition, as denosumab has no known renal toxicity, it may be the preferred choice over bisphosphonates in patients with baseline renal insufficiency or receiving nephrotoxic therapies. However, other toxicities, including osteonecrosis of the jaw and hypocalcemia, appear to be class effects of agents that potently inhibit osteoclast activity and are associated with both denosumab and bisphosphonate use. The data presented highlight the differences associated with intravenous bisphosphonate and denosumab use as well as confirm the essential role bone-modifying agents play in maintaining the quality of life for patients with bone metastases.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 17%
Researcher 5 17%
Student > Master 5 17%
Student > Ph. D. Student 2 7%
Student > Bachelor 2 7%
Other 4 14%
Unknown 6 21%
Readers by discipline Count As %
Medicine and Dentistry 13 45%
Agricultural and Biological Sciences 3 10%
Nursing and Health Professions 2 7%
Psychology 2 7%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 2 7%
Unknown 6 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Biologics: Targets & Therapy
#221
of 274 outputs
Outputs of similar age
#135,504
of 173,277 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,277 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.